EPH80 Survival and Best Recorded Response (BRR) in Patients With Advanced Merkel Cell Carcinoma (MCC): Analysis of a Prospective German MCC Registry Study (MCC TRIM) of the German Dermatologic Cooperative Oncology Group
Seyed Hamidreza Mahmoudpour(Johannes Gutenberg University Mainz), Selma Ugurel(Klinikum Bielefeld), Patrice Verpillat(Centre National de la Recherche Scientifique), Dirk Schadendorf(National Center for Tumor Diseases), Emmanuelle Boutmy(Merck KGaA, Darmstadt (Germany)), Friedegund Meier(National Center for Tumor Diseases), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Stephan Grabbe(Goethe University Frankfurt), Fabian Ziller(Vivantes Klinikum), Martin Sachse(Institut Pasteur), Margarita Shlaen, Lisa Zimmer(The University of Sydney), Changbo Fu(Fudan University), Anthony F. Milano, Ulrike Leiter(University of Tübingen), C. Gerbhardt(Universität Hamburg), J.C. Backer(Essen University Hospital), Rudolf Herbst(Helios Klinikum Erfurt), Steven J. Hoff(Merck KGaA, Darmstadt (Germany)), Claudia Pföhler(Saarland University)
Cited by 0
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k